SCHEMBL18407477

SCHEMBL18407477

CC(C)c1ccc(C2CCOCC2)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 6/20 0.42
MAOA P21397 1/20 0.41
RPS6KA3 P51812 1/20 0.38
PDE2A O00408 6/20 0.38
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
KIF11 P52732 1/20 0.34
PDE9A O76083 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17914538 0.88 PDE2A (0.44) OPRL1PDE2ACHRNB2CHRNA4
SCHEMBL15577422 0.87 RPS6KA3 (0.38) OPRL1MAOARPS6KA3PDE2ACHRNB2
SCHEMBL24664746 0.85 PDE2A (0.40) OPRL1PDE2ACHRNB2CHRNA4
SCHEMBL13499048 0.85 APP (0.41) OPRL1PDE2ACHRNB2CHRNA4
SCHEMBL25693956 0.83 CHRNB2 (0.37) PDE2ACHRNB2CHRNA4GAA
SCHEMBL16285922 0.83 APP (0.43) OPRL1PDE2ACHRNB2CHRNA4
SCHEMBL22502744 0.82 PDE2A (0.41) OPRL1PDE2ACHRNB2CHRNA4
SCHEMBL15785387 0.81 HTR6 (0.45) PDE2ACHRNB2CHRNA4TLR9TLR8
SCHEMBL19245044 0.81 CHRNB2 (0.35) OPRL1CHRNB2CHRNA4KIF11GAA
SCHEMBL11977022 0.79 TLR9 (0.44) OPRL1PDE2ACHRNB2CHRNA4TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-11382949-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-07-12 US disclosed
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2022-03-31 US disclosed
US-11230571-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-01-25 US disclosed
US-20200354408-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2020-11-12 US disclosed
US-10793604-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2020-10-06 US disclosed
US-20190307838-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2019-10-10 US disclosed
US-20190248840-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2019-08-15 US disclosed
US-10344056-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2019-07-09 US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
US-20170022253-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344056-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 OPRL1 2349/4885MAOA 2761/4885RPS6KA3 2648/4885
US-20170022253-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP OPRL1 2560/4885MAOA 3007/4885RPS6KA3 3432/4885
US-11382949-B2 Anthelmintic depsipeptide compounds ENPP2, ROCK2, RRP12 OPRL1 1493/4885MAOA 2904/4885RPS6KA3 1018/4885
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885
US-10793604-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP OPRL1 2560/4885MAOA 3007/4885RPS6KA3 3432/4885
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885
US-20190248840-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885
US-20190307838-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS ENPP2, ROCK2, RRP12 OPRL1 1493/4885MAOA 2904/4885RPS6KA3 1018/4885
US-20200354408-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP OPRL1 2560/4885MAOA 3007/4885RPS6KA3 3432/4885
US-11230571-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP OPRL1 2279/4885MAOA 3170/4885RPS6KA3 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.